Results 261 to 270 of about 262,635 (315)
Treatment of chronic hepatitis B [PDF]
The Lancet Infectious Diseases, 2001 This review updates the treatment of chronic hepatitis B infection. Complete eradication of hepatitis B virus (HBV) is not possible, so the efficacy of treatment has to be assessed by whether it can limit long-term cirrhosis-related complications. We discuss two major groups of treatments--immunomodulators (interferon alfa, thymosin alpha1, therapeutic
Lai, CL, Yuen, MF
openaire +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Current Treatment Options in Gastroenterology, 2004
Interferon alpha, lamivudine, and adefovir are the three drugs currently approved for the treatment of chronic hepatitis B virus (HBV). There are pros and cons associated with the use of each drug. Individualization of therapy, based upon factors such as patient comorbidities, response to prior therapies, and stage of disease, is recommended.
Stephanie Straley, Norah A. Terrault
openaire +2 more sources
Interferon alpha, lamivudine, and adefovir are the three drugs currently approved for the treatment of chronic hepatitis B virus (HBV). There are pros and cons associated with the use of each drug. Individualization of therapy, based upon factors such as patient comorbidities, response to prior therapies, and stage of disease, is recommended.
Stephanie Straley, Norah A. Terrault
openaire +2 more sources
Treatment of chronic hepatitis B
Journal of Viral Hepatitis, 2005Summary. In the last years, marked progress has been made in the treatment of chronic hepatitis B. The efficacy of lamivudine, the first nucleoside analogue available, is limited by the high incidence of resistance. Adefovir, which was recently approved has a comparable efficacy with a very low frequency of resistance.
Patrick Marcellin +2 more
openaire +5 more sources
Interferon in chronic hepatitis B
Antiviral Research, 1994In patients with typical chronic hepatitis B (HBsAg, HBeAg, HBV-DNA-positive), treatment with interferon-alpha must be carried out for 4-6 months on an alternate-day basis and dosage should be not less than 5 million units/square meter of body surface.
SARACCO, Giorgio Maria +2 more
openaire +4 more sources
BMJ, 2009
Clinical course and treatment of this infection common in Asia and the challenge of its global ...
Ching Lung Lai, Arthur C K Wong
openaire +2 more sources
Clinical course and treatment of this infection common in Asia and the challenge of its global ...
Ching Lung Lai, Arthur C K Wong
openaire +2 more sources
Annals of Internal Medicine, 1988
Excerpt To the Editor:Perrillo and colleagues (1) make an important contribution to the study of chronic hepatitis B treatment.
openaire +3 more sources
Excerpt To the Editor:Perrillo and colleagues (1) make an important contribution to the study of chronic hepatitis B treatment.
openaire +3 more sources
Treatment of chronic hepatitis B
Nature Clinical Practice Gastroenterology & Hepatology, 2006Treatment of chronic hepatitis B has improved substantially over the past five years. Pegylated interferon alpha2a and entecavir have been approved by the FDA and joined the armamentarium of therapies that includes inteferon alpha (IFN-alpha), lamivudine, and adefovir dipivoxil. Several key questions come to mind regarding treatment. Who should receive
Sonia S. Kupfer +2 more
openaire +3 more sources